A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma

Trial Profile

A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs GSK 1059615 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Aug 2009 Actual number of patients (11) added as reported by ClinicalTrials.gov
    • 12 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 15 Jul 2008 Status changed from initiated to recruiting according to M.D. Anderson website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top